November 19th 2020
analyst reports
November 19th 2020
press releases
November 19th 2020
press releases
November 11th 2020
analyst reports
This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.
November 11th 2020
analyst reports
November 10th 2020
press releases
Upcoming Events
Whats next.
December 8th 2020 - December 12th 2020
read more
January 11th 2021 - January 14th 2021
read more
February 23rd 2021 - February 26th 2021
read more
passion.
It takes a great deal of passion on the fight against cancer. We put our heart and soul into winning it.
know-how.
Our goal is to gather the strongest forces, the brightest minds and the most dedicated employees.
research.
Accurate research is the strong foundation for developing potential in effective treatment.
What is LAG3?
Lymphocyte-activation gene 3, or LAG-3 (LAG3), is a cell surface molecule with biologic effects on T cell function.
LAG3 is being used for many cancer immunotherapy treatments including Eftilagimod Alpha from Immutep.
